Kornimate/medical-research-clean huggingface dataset:
laparoscopic splenectomy in isolated high grades splenic injuries

Conditions: Laparoscopic Surgery

Summary: background: trauma laparoscopic splenectomy has no defined reasons. compared trauma patient characteristics and results with laparoscopic and open splenectomies. methods: patients aged 15 or older with blunt splenic injuries from january 2012 to july 2017 needed splenectomy. demographics, splenic damage grade, approach (open or laparoscopic), surgery duration, intra-operative blood loss, transfusions, hospital stay, complications, and death were variables.

the spleen might be injured in left lower chest or upper abdomen trauma. rib cage, diaphragm, pancreas, and bowel injuries may occur with splenic injuries. hemodynamic instability, a rising heart rate, and low blood pressure are symptoms of damage, however the mechanism of injury requires a high index of suspicion.

Eligibility criteria:
inclusion criteria: * • at least 15 years old. * male and female (not pregnant) patients; • sonar and ct scans before surgery showed single splenic damage; exclusion criteria: * • other damage to the abdomen, thorax, or nerves were found before surgery. * good use of non-surgical treatment or embolization * woman who is pregnant. * splenic cuts that go deep. * previous surgery in the upper abdomen using a laparoscopic method. • other injuries to the abdomen found during surgery, such as liver, intestine, or bladder injuries.

Keywords: laparoscopy laparotomy non-penetrating splenectomy
an observational study of chinese multiple myeloma patients treated with velcade

Conditions: Multiple Myeloma

Summary: the purpose of this study is to acquire information on the usage, effectiveness, safety, and levels of health care resource utilization associated with velcade therapy in recurrent and refractory multiple myeloma patients who are initiating velcade and various combination therapies within the approved indication in a naturalistic setting.

this is a national, multi-center (study conducted in multiple sites), non-interventional (a scientific study where one or more investigators monitor one or more patients being treated with the same medication), observational study (a scientific study to make a clear and easy understanding of the cause and effect relationship) of chinese multiple myeloma patients treated with velcade. the study consists of 3 phases, including, screening phase, treatment phase, and follow up phase. in the screening phase, data will be collected on the basis of patient's demographic status, components of disease severity assessment, and potential prognostic factors. data on prior cancer treatments will be collected retrospectively at baseline for patients receiving cancer treatment prior to receiving velcade. in the treatment phase, velcade is administered intravenously for a 2-week treatment period followed by a 10-day rest period. each treatment cycle consists of 21 days. prospective (in which the participants are first identified and then followed forward as time passes) observational data will be collected during treatment with velcade. in the follow up phase, patients will be followed for up to three years to document long-term survival data. for patients who reinitiate velcade, data collection should follow velcade treatment period documentation process. safety evaluations will be based on the incidence, intensity, and types of adverse events. the total duration of the study is set prospectively for three years from the date of the patients' initiation of velcade.

Eligibility criteria:
inclusion criteria: * must give informed consent in agreement with local legislation * must not have any contraindication listed in package insert exclusion criteria: * patients currently participating in another investigational study of velcade or any other medication * patients with severe hepatic or renal impairment * patients with platelet count below 25000/μl * patients who are considered disqualified for the study by the investigators

Keywords: multiple myeloma cancer velcade bortezomib chinese patients
lavender oil on preoperative anxiety and sedation requirement in general anaesthesia

Conditions: Preoperative Anxiety

Summary: assessment of how lavender oil reduces preoperative anxiety and subsequently influences requirement of induction agents for general anesthesia.

this study aims to use aromatherapy (lavender oil) to reduce preoperative anxiety among female patients coming for elective surgeries under general anesthesia. as a consequence of that, the effect is also evaluated on how that influences the amount of intravenous sedation is required during induction for general anesthesia.

Eligibility criteria:
inclusion criteria: * age 18-65 * female exclusion criteria: * patients on b-blockers and or antidepressants. * bmi \> 35kg/m2 * history of atopy * history of alcoholism, substance abuse, smoking * patients with cancer

Keywords: lavender oil, propofol
what benefit with a new stapler device in the surgical treatment of obstructed defecation?

Conditions: Rectal Prolapse

Summary: this randomized study was designed to compare the 2 year clinical and functional results with the starr procedure using a new curved cutter stapler or the same operation done with 2 traditional circular staplers.

from january to november 2006, 80 women were selected, with clinical examination, constipation score, colonoscopy, anorectal manometry, and perineography and randomly assigned to 2 groups: 40 patients underwent stapled transanal rectal resection with two staplers pph-01 (ethicon endosurgery inc, pomezia, italy) (starr group) and 40 had the same operation with new, curved multi-fire stapler contour r transtar tm (transtar group). patients were followed up with clinical examination, constipation score, and perineography.

Eligibility criteria:
inclusion criteria: * rectal prolapse * rectocele * ods score \> 15 * continence score \< 3 * resting pressure \> 40 mm/hg exclusion criteria: * previous anorectal surgery * ods score \< 15 * continence score \> 3 * resting pressure \< 40 * concomitant pelvic floor diseases * psychiatric diseases * absolute contraindications to surgery

Keywords: ods stapled transanal rectal resection
menopur and rekovelle combination study

Conditions: Fertility Disorders

Summary: this study proposes to evaluate the effect of adding hp-hmg (menopur) to follitropin delta in a "mixed protocol" regimen, using an individualized, fixed dose of follitropin delta based on the established algorithm, combined with a variable, adjustable dose of menopur based on body weight and ovarian reserve.

the initial dose of follitropin delta will be determined at enrolment by the analysis of serum amh on days 2 to 5 of the menstrual cycle preceding the ivf treatment cycle and body weight in kg the initial dose of hp-hmg to be added on top of follitropin delta will be determined at enrolment by the total follitropin delta dose and body weight in kg

Eligibility criteria:
inclusion criteria: * women 18 to 40 years of age undergoing their first ivf/icsi cycle * diagnosed with unexplained infertility, tubal infertility, endometriosis stage i/ii, or with partners diagnosed with male factor infertility * regular menstrual cycles of 24-35 days * presence of both ovaries * early follicular phase fsh serum concentration \<10 iu/l measured between day 2 to day 5 of menstrual cycle within the previous 12 months * ejaculated sperm (fresh or frozen) for insemination exclusion criteria: * inability to consent * endometriosis stage iii and iv * high risk of ohss (amh ≥ 35 pmol/l) * history of recurrent miscarriages defined as ≥ 3 consecutive losses * women undergoing egg donation * women participating in any other research project * use of hormonal preparations (except for thyroid medication) during the last menstrual cycle * hypersensitivity to follitropin delta and/or hp-hmg

Keywords: ovarian response in vitro fertilization controlled ovarian stimulation
the effect of education given to patients on pre- and post-operative anxiety and preparation for discharge

Conditions: Kidney Calculi

Summary: the data of the randomized controlled experimental research were collected at atatürk university health application and research hospital urology clinics between november 2021 and may 2022. the study sample consisted of 122 patients (61 in the training group, 61 in the control group) who were selected by the simple random sampling method and met the research inclusion criteria.

ureteroscopy (urs) is an up-to-date method that is widely used in the diagnosis and treatment of ureteral diseases. apart from the diagnostic purposes of urs, the most common use is to intervene in ureteral stones. the vast majority of ureteral stones are treated endoscopically. a double-j (dj) stent is often placed after ureteroscopy. the purpose of the stent is to prevent obstruction, renal colic, and deterioration of renal function. the fact that the dj stent will remain in the patient for a certain period of time (approximately 3-4 weeks) causes anxiety in the patient. however, approximately 80% of patients with dj stent implantation have urinary system symptoms that impair their quality of life. frequent urination (50-60%), sudden urge to urinate (57-60%), pain on urination (40%), incomplete evacuation (76%), flank pain (19-32%), suprapubic pain (30%) , incontinence and hematuria (25%) are the symptoms seen. patients with dj stent implanted after ureteroscopy surgery need more information, support, explanation and help to cope with the effects of these symptoms in the clinic and at home. in this context, it is important to provide an individualized and comprehensive education that includes the home care process before and after the urs. it has been determined in the literature that training before surgery reduces anxiety, pain level, complication and depression rates, and increases patient satisfaction in the postoperative period. no study has been found in the literature examining the effects of education given to patients with urs on their post-operative anxiety and readiness for discharge. in this context, this study will provide evidence-based data to the literature by investigating the effects of training given to patients with urs and dj stent implantation on pre- and postoperative anxiety and readiness for discharge.

Eligibility criteria:
inclusion criteria: * agreeing to participate in the research and volunteering, * those between the ages of 18-65, * having urs surgery for the first time due to stone and temporary dj stent placed, * patients whose cognitive level scales were suitable for application were included in the study. exclusion criteria: * having urs surgery for non-stone causes, * permanent stent placed, * leaving work voluntarily, * patients with major hearing and vision problems were not included in the study.

Keywords: anxiety, double j stent, nurse, education, ureteroscopy
effect of normatec pump for relief of leg edema in patients with right heart failure

Conditions: Right Heart Failure; Cor Pulmonale

Summary: mobilization of fluid from the legs with the normatec pump in patients with right heart failure, may empty the "reservoir" in the legs from excessive fluid, enabling fluid overload to collect there rather than in the liver or in other third spaces. thus, we hypothesize that patients will lose weight, feel better, look better, be less prone to infections in their legs and to congestion of the liver.

the protocol will be divided into 2 parts: 1. the initial pumping phase will be an in-hospital study, short term study. patients will be randomly assigned to conventional/conservative treatment or to pump therapy. within 24 hours of admission patients assigned to pump therapy will be recruited for the study and will begin therapy according to the protocol outlined in the table below. these patients will not be given diuretics unless required to because of shortness of breath with suspected left heart failure. individualized programs regarding pumping frequency and pump parameters will be set for each patient and will be adjusted during the first few days and maintained throughout the study unless there is a reason to modify them. data on both the conventional/conservative and the pump arms of the study will be collected at similar intervals. the duration of the in-hospital period will not be extended because of the study and is expected to be 3-7 days. 2. an intermediate-term study in which the patients from the phase 1 study will be ambulatory. during this phase of the study the effect of continuous maintenance and optimization will be monitored. patients will come to the hospital for their pumping session at which time the protocol tests will be performed. patients that were assigned to the conventional/conservative arm in phase 1 will be examined as per protocol at 1, 2 and 3 weeks after admission but bnp levels will be repeated only after the 3rd week. 3. at 3 and 6 months after admission, the "long term" phase of the study, a systematic investigation regarding repeat hospitalizations and their causes will be carried out by telephone interview and by a review of admission data from hospital records.

Eligibility criteria:
inclusion criteria: * hospitalized patients * adults * right heart failure secondary to pulmonary hypertension (cor pulmonale) * pronounced leg edema exclusion criteria: * patients in sepsis * hemodynamically unstable * renal failure (creatinine \>2 mg%) * deep vein thrombosis * pregnancy * psychiatric/noncompliant patients * patients who will not sign the informed consent form

Keywords: edema right heart failure cor pulmonale pump leg compression
genotyping influences outcome of coronary artery stenting

Conditions: Myocardial Ischemia; CLOPIDOGREL, POOR METABOLISM of (Disorder)

Summary: this study evaluated epidemiology and clinical outcome of clopidogrel related various genotyping in korean patients who had undergone percutaneous coronary intervention as a all comer registry form.

this study evaluates the relationship between clopidogrel related various genotyping, epidemiology and clinical outcome of patient who had undergone percutaneous coronary intervention. clopidogrel resistance was measured with verifynow, which is a device that can monitor platelet inhibition of clopidogrel. genes which are known to be related with clopidogrel resistance were evaluated; (1-3) cyp 2c19 \*2, \*3, \*17, (4) pon1 q192r, (5) abcb1 3435c-\>t, (6) p2y12, (7) cyp 2c9 \*3.

Eligibility criteria:
inclusion criteria: * written informed consent * older than 20 years * all percutaneous coronary intervention patients within 1 month exclusion criteria: * pregnancy * life expectancy below 1 year * known aspirin or clopidogrel allergy
cancer, vulnerability, and financial quality of life: a mixed methods study

Conditions: Cancer

Summary: the primary purpose of this study is to examine how vulnerabilities in psychological and social situations affect financial quality of life.

the primary purpose of this study is to examine how vulnerabilities in psychological and social situations affect financial quality of life. for people who are experiencing financial hardship, a cancer diagnosis can be devastating. for others, cancer may cause or even worsen financial stress, for example, with their work, their ability to maintain benefits such as health insurance, their ability to pay bills, and their ability to get the cancer treatment they need. the impact of cancer on financial quality of life is an important area of study within cancer care. considering the financial burden of cancer also lends greater appreciation for the problems that people face if they cannot handle cancer's costs, or if needed resources are either not present or are too stretched to help with the care they need. for this study, up to 180 cancer patients will be interviewed with a written questionnaire. of this group, 15 people will also be asked if they would like to participate in a follow-up personal interview with the researcher. the major hypothesis of this study is: the greater the vulnerabilities in predisposing factors and enabling factors, the greater the need factors with respect to cancer diagnosis and treatment, and the lower the perceived ability to adhere to treatment, the poorer will be the financial quality of life.

Eligibility criteria:
inclusion criteria: * any cancer patient over the age of 18 who can speak and understand english and can provide informed consent exclusion criteria: * pediatric patients; non-english-speaking patients

Keywords: any type of cancer
analysis of various treatment methods of granulomatous lobular mastitis

Conditions: Granulomatous Mastitis

Summary: granulomatous lobular mastitis (glm) is a rare benign breast disease that is difficult to distinguish from breast cancer based on clinical and imaging findings, and there is currently no standard treatment. this study aims to analyze the clinical characteristics and demographic data of glm patients and to compare the overall effectiveness of three treatment methods: surgery alone, triple anti-tuberculosis drug therapy alone, and combined surgery with triple anti-tuberculosis drug therapy, with the goal of providing new insights for clinical treatment.

in recent years, the incidence of this disease has been increasing annually. the incidence of glm is region-specific, being higher in mediterranean regions and asian countries. the etiology is currently unclear, but many studies suggest that glm is associated with autoimmune disorders, hormonal imbalances, and microbial infections . glm has a long course, is difficult to treat, and prone to recurrence, causing significant trauma to the patient's breast appearance and overall well-being. currently, the main treatment methods for glm include surgical treatment, drug therapy, combined surgery with drug therapy, and close observation. surgical treatment options mainly include abscess incision and drainage, segmental resection, subcutaneous mastectomy, mastectomy, and breast reconstruction. although surgical treatment can rapidly improve the condition, the recurrence rate reported in the literature ranges from 5% to 50% . although glm is a benign disease, it can severely impact the patient's normal life, causing physical and psychological trauma. however, few studies have included patients' subjective treatment experiences in the evaluation of treatment outcomes. to date, there have been no studies comparing the efficacy of three treatment methods (surgery alone, triple anti-tuberculosis drug therapy alone, and combined surgery with triple anti-tuberculosis drug therapy) in the same population of glm patients. this study aims to compare the efficacy and patient satisfaction of these three treatment methods, with the hope of providing new insights for clinical treatment options.

Eligibility criteria:
inclusion criteria: * non-lactating and aged 15-65 years * histopathological confirmation of glm * normal liver and kidney function exclusion criteria: * lactating and pregnant women * allergies to rifampin, isoniazid, or ethambutol * concurrent malignant breast tumors * severe underlying diseases * other conditions deemed unsuitable by the investigator and * refusal to participate in the study

Keywords: granulomatous lobular mastitis surgical treatment antituberculosis therapy surgery combined with anti-tuberculosis therapy
antiplatelet therapy effect on extracellular vesicles in acute myocardial infarction

Conditions: Myocardial Infarction

Summary: platelet activation and aggregation leads to myocardial infarction. platelet p2y12 receptors are essential for platelet activation. antagonists against the p2y12 receptor, which are established in secondary prevention of myocardial infarction, have unexplained anti-inflammatory effects. a novel p2y12 receptor antagonist ticagrelor reduced infection-related mortality compared to clopidogrel, previous standard treatment for patients with myocardial infarction. activated platelets release pro-inflammatory and procoagulant platelet extracellular vesicles. the investigators assume that decrease in infection-related mortality in patients treated with ticagrelor may be explained by greater inhibition of the release of platelet vesicles by ticagrelor, compared to clopidogrel. this study is expected to identify an additional mechanism of action of ticagrelor, which might contribute to the observed clinical benefits in patients treated with ticagrelor.


Eligibility criteria:
inclusion criteria: * age \> 18 years * informed consent to participate in the study * percutaneous coronary intervention with stent implantation due to first s t elevation myocardial infarction, or first non s t -elevation myocardial infarction * administration of a loading dose of clopidogrel exclusion criteria: * known coagulopathy * known history of bleeding disorder * suspicion of intracranial haemorrhage * need for oral anticoagulation therapy * administration of glycoprotein (gp) ii b - iii a antagonists * cardiogenic shock * severe chronic renal failure (estimated glomerular filtration rate \< 30 ml/min) * severe liver insufficiency * chronic dyspnea * increased risk of bradycardia * autoimmune disease * infectious disease * neoplasms * pregnancy * study drug intolerance * co-administration of ticagrelor or clopidogrel with strong cyp3a4 inhibitors * participation in any previous study with ticagrelor or clopidogrel

Keywords: extracellular vesicles inflammation thrombosis antiplatelet drugs
naturalistic safety registry of celecoxib (celebrex(r)) and nsaids in juvenile idiopathic arthritis

Conditions: Arthritis, Juvenile Rheumatoid

Summary: this multi-center observational registry will collect long-term safety data on patients treated with celecoxib or non-selective nonsteroidal anti-inflammatory drugs (nsnsaids) as used in clinical practice for the treatment of juvenile idiopathic arthritis (jia).

none study has been terminated early (lslv = 09jan2012) due to release of the postmarketing commitment by the us fda. the study was stopped for futility/change in treatment paradigm that minimizes chronic nsaid use and not for safety concerns.

Eligibility criteria:
inclusion criteria: * age at least 2 years but less than 18 years; jia of any of the following subtypes: oligoarthritis, polyarthritis, or stable systemic disease; * new treatment (started not more than 6 months prior) with one nsaid (celecoxib or nsnsaid). exclusion criteria: * patients with the following jia subtypes: active systemic disease, psoriatic arthritis, enthesitis-related arthritis, or undifferentiated arthritis; * patients with reiter's syndrome; patients unlikely to complete 2 years of follow up; * patients who need to use multiple nsaids at the same time.

Keywords: celecoxib cox-2 nsaids observational study noninterventional study cohort study registry epidemiologic study pediatrics rheumatology phase iv study